Return investor SBCVC contributed to a round that took the total raised by the cancer screening system developer past the $130m mark.
China-based cancer diagnostics technology provider New Horizon Health closed a $20m series D round on Tuesday featuring SBCVC, an investment vehicle for telecommunications firm SoftBank.
Private equity firm Omniscient led the round, which included family office Exome Asset Management, venture capital firm Qiming Venture Partners and Duke University’s investment management arm, Duke Management Company, according to a WeChat post by New Horizon.
Founded in 2013, New Horizon produces cancer screening technology and has developed home testing systems for cervical, gastric…
